menu
    • menu

    Company profile for Protagenic Therapeutics

    NEW Drugs in Dev: 2
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Protagenic Therapeutics, Inc. (OTCQB: PTIX) is a pre-clinical biopharmaceutical company endeavoring to develop first-in-class neuro-active peptides into human therapeutics to treat several stress related disorders.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Protagenic TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1625th Ave, New York, New York, United States.
    Telephone
    Telephone
    213-260-4342
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://protagenic.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    PT00114 Phase 1 Multiple-Dose Study Results
    PT00114 Phase 1 Multiple-Dose Study Results

    09 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-09/results-from-phase-1-multiple-dose-study-of-pt00114

    PHARMIWEB
    09 Dec 2025
    Share Share
    Protagenic Therapeutics Receives Nasdaq Non-Compliance Notice
    Protagenic Therapeutics Receives Nasdaq Non-Compliance Notice

    27 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-27/protagenic-therapeutics-announces-receipt-of-nasdaq-non-compliance-notice

    PHARMIWEB
    27 Nov 2025
    Share Share
    Protagenic Therapeutics Completes Phase 1 MAD Study Enrollment
    Protagenic Therapeutics Completes Phase 1 MAD Study Enrollment

    13 Nov 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-11-13/protagenic-therapeutics-announces-completion-of-enrollment-and-dosing-in-phase-1-mad-study

    PHARMIWEB
    13 Nov 2025
    Share Share
    Protagenic Updates on Form 10-Q Filing and Nasdaq Compliance
    Protagenic Updates on Form 10-Q Filing and Nasdaq Compliance

    22 Aug 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/protagenic-therapeutics-provides-update-on-form-10-q-filing-timeline-1064488

    ACCESSWIRE
    22 Aug 2025
    Share Share
    Protagenic Therapeutics Moves PT00114 to Phase 1 Trial
    Protagenic Therapeutics Moves PT00114 to Phase 1 Trial

    21 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-21/protagenic-therapeutics-advances-pt00114-into-multiple-dose-phase-1-trial-positioning-for-phase-2-i

    PHARMAWEB
    21 Aug 2025
    Share Share
    Protagenic Therapeutics Granted New Japan Patent for Stilbenoid
    Protagenic Therapeutics Granted New Japan Patent for Stilbenoid

    30 Jul 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/07/30/3124067/0/en/Protagenic-Therapeutics-Announces-Grant-of-new-patent-in-Japan-for-its-Modified-Stilbenoid-Program-Drug-Candidates.html

    GLOBENEWSWIRE
    30 Jul 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search